

# Tofacitinib in UC: A practical guide

**18:45–19:45**

**Thursday 7 March 2019**

**Plenary Hall, Bella Center  
Copenhagen, Denmark**

Summary of product characteristics available at Booth 3.



**Please join us for a Pfizer-sponsored symposium  
during the [14th Congress of ECCO](#).**

The objectives of this meeting are to:

- Communicate and provide clinical context on key tofacitinib efficacy and safety data in patients with UC
- Provide practical guidance for clinicians concerning tofacitinib treatment in patients with UC

This programme is not affiliated with ECCO.  
This meeting is organised and funded by Pfizer © 2019 Pfizer Inc.  
All rights reserved. January 2019. PP-XBD-GLB-0178

**Pfizer** Gastroenterology

# Tofacitinib in UC: A practical guide

## Agenda

---

- 18:45–18:50** **Welcome and introductions**  
Simon Travis, DPhil, FRCP
- 
- 18:50–19:05** **Tofacitinib: An effective option for moderate-to-severe UC**  
Simon Travis, DPhil, FRCP
- 
- 19:05–19:20** **Exploring the tofacitinib safety profile**  
Axel Dignass, MD, PhD
- 
- 19:20–19:40** **The practicalities of using tofacitinib in the clinic**  
Peter Irving, MA, MD, FRCP
- 
- 19:40–19:45** **Q&A**  
All faculty
- 



### **Simon Travis, DPhil, FRCP**

Professor of Clinical Gastroenterology  
Translational Gastroenterology Unit  
Oxford University Hospitals  
Oxford, United Kingdom



### **Axel Dignass, MD, PhD**

Director of the Department of Medicine I  
Agaplesion Markus Hospital  
Goethe University  
Frankfurt am Main, Germany



### **Peter Irving, MA, MD, FRCP**

Consultant Gastroenterologist  
Guy's and St Thomas NHS Foundation Trust  
London, United Kingdom